吃西罗莫司片有什么注意事项？

What should you pay attention to when eating (Leipaming)? Sirolimus tablets (rapamin) are suitable for patients aged 13 or above who have received kidney transplants to prevent organ rejection. It is recommended that sirolimus tablets (rapamin) be used in combination with cyclosporine and corticosteroids. Monitoring of therapeutic drug plasma concentrations is recommended for all patients receiving sirolimus tablets (rapamin). Sirolimus tablets (rapamin) should only be used by physicians experienced in immunosuppressive therapy and in the management of kidney transplant patients. Patients receiving this drug should be treated in an institution with appropriate laboratory and ancillary medical facilities and personnel.

Precautions for Sirolimus Tablets (Repamin):

Hypersensitivity reactions: Hypersensitivity reactions associated with the administration of sirolimus tablets (rapamin) include anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and allergic vasculitis.

Angioedema: Taking sirolimus tablets (rapamin) has been associated with the formation of angioedema. The risk of angioedema development may be increased when sirolimus (rapamin) is used concomitantly with other drugs known to cause angioedema, such as angiotensin-converting enzyme inhibitors.

Hyperlipidemia: Use of rapamycin in renal transplant patients has the potential to cause elevations in serum cholesterol and triglycerides requiring treatment. Therefore, patients must be monitored for the development of hyperlipidemia.

Interactions with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp: Coadministration of rapamycin with strong inhibitors of CYP3A4 and/or P-gp (e.g., ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin) or strong inducers of CYP3A4 and/or P-gp (e.g., rifampicin and rifabutin) is not recommended. Sirolimus tablets (rapamin) are extensively metabolized in the intestinal wall and liver by the CYP3A4 isoenzyme. Inhibitors of CYP3A4 can slow down the metabolism of sirolimus and increase the plasma concentration of sirolimus tablets (rapamin). Inducers of CYP3A4 accelerate the metabolism of sirolimus tablets (rapamin) and decrease the plasma concentration of sirolimus tablets (rapamin).

The above are the precautions for (Leipaming) provided by our medical companion tour.

Recommended related hot articles: /newsDetail/76761.html